Misfolded proteinase K-resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α-synucleinopathies

被引:288
作者
Neumann, M
Kahle, PJ
Giasson, BI
Ozmen, L
Borroni, E
Spooren, W
Müller, V
Odoy, S
Fujiwara, H
Hasegawa, M
Iwatsubo, T
Trojanowski, JQ
Kretzschmar, HA
Haass, C
机构
[1] Univ Munich, Lab Alzheimers & Parkinsons Dis Res, Dept Biochem, Adolf Butenandt Inst, D-80336 Munich, Germany
[2] Univ Munich, Dept Neuropathol, D-80336 Munich, Germany
[3] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[4] F Hoffmann La Roche & Co Ltd, Pharma Res, CH-4002 Basel, Switzerland
[5] Univ Tokyo, Dept Neuropathol & Neurosci, Grad Sch Pharmaceut Sci, Tokyo, Japan
关键词
D O I
10.1172/JC1200215777
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The pathological modifications of alpha-synuclein (alphaS) in Parkinson disease and related diseases are poorly understood. We have detected misfolded alphaS in situ based on the proteinase K resistance (PK resistance) of alphaS fibrils, and using specific antibodies against S129-phosphorylated alphaS as well as oxidized alphaS. Unexpectedly massive neuritic pathology was found in affected human brain regions, in addition to classical alphaS pathology. PK resistance and abnormal phosphorylation of alphaS developed with increasing age in (Thy1)-h[A30P] alphaS transgenic mice, concomitant with formation of argyrophilic, thioflavin S-positive, and electron-dense inclusions that were occasionally ubiquitinated. alphaS pathology in the transgenic mice was predominantly in the brainstem and spinal cord. Astrogliosis was found in these heavily affected tissues. Homozygous mice showed the same pathology approximately one year earlier. The transgenic mice showed a progressive deterioration of locomotor function. Thus, misfolding and hyperphosphorylation of alphaS may cause dysfunction of affected brain regions.
引用
收藏
页码:1429 / 1439
页数:11
相关论文
共 52 条
[1]   Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system [J].
Abeliovich, A ;
Schmitz, Y ;
Fariñas, I ;
Choi-Lundberg, D ;
Ho, WH ;
Castillo, PE ;
Shinsky, N ;
Verdugo, JMG ;
Armanini, M ;
Ryan, A ;
Hynes, M ;
Phillips, H ;
Sulzer, D ;
Rosenthal, A .
NEURON, 2000, 25 (01) :239-252
[2]   Pure autonomic failure in association with human α-synucleinopathy [J].
Arai, K ;
Kato, N ;
Kashiwado, K ;
Hattori, T .
NEUROSCIENCE LETTERS, 2000, 296 (2-3) :171-173
[3]   Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for α-synuclein [J].
Arawaka, S ;
Saito, Y ;
Murayama, S ;
Mori, H .
NEUROLOGY, 1998, 51 (03) :887-889
[4]   Immunoelectron-microscopic demonstration of NACP/α-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies [J].
Arima, K ;
Uéda, K ;
Sunohara, N ;
Hirai, S ;
Izumiyama, Y ;
Tonozuka-Uehara, H ;
Kawai, M .
BRAIN RESEARCH, 1998, 808 (01) :93-100
[5]   Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease [J].
Auluck, PK ;
Chan, HYE ;
Trojanowski, JQ ;
Lee, VMY ;
Bonini, NM .
SCIENCE, 2002, 295 (5556) :865-868
[6]   Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid [J].
Conway, KA ;
Harper, JD ;
Lansbury, PT .
BIOCHEMISTRY, 2000, 39 (10) :2552-2563
[7]   Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease [J].
Conway, KA ;
Harper, JD ;
Lansbury, PT .
NATURE MEDICINE, 1998, 4 (11) :1318-1320
[8]  
DAPRADA M, 1989, J PHARMACOL EXP THER, V248, P400
[9]   Where does Parkinson disease pathology begin in the brain? [J].
Del Tredici, K ;
Rüb, U ;
de Vos, RAI ;
Bohl, JRE ;
Braak, H .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2002, 61 (05) :413-426
[10]  
Dickson DW, 1999, BRAIN PATHOL, V9, P721